• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Antimicribial Agents and Chem. Evolution of oseltamivir resistance mutations in influenza A(H1N1) and A(H3N2) viruses during selection in experimenta

tetano

Editor, Senior Moderator
Published ahead of print 11 August 2014, doi: 10.1128/AAC.02956-14 AAC.02956-14

Evolution of oseltamivir resistance mutations in influenza A(H1N1) and A(H3N2) viruses during selection in experimentally-infected mice

Andr?s Pizzorno,
Yacine Abed,
Pier-Luc Plante,
Julie Carbonneau,
Mariana Baz,
Marie-?ve Hamelin,
Jacques Corbeil and
Guy Boivin*

Research Center in Infectious Diseases of the CHU of Qu?bec and Laval University, Qu?bec City, QC, Canada.

ABSTRACT

The evolution of oseltamivir resistance mutations during selection through serial passages in animals is still poorly described. Herein, we assessed the evolution of neuraminidase (NA) and hemagglutinin (HA) genes of influenza A/WSN/33 (H1N1) and A/Victoria/3/75 (H3N2) viruses recovered from lungs of experimentally-infected BALB/c mice receiving suboptimal doses (0.05 and 1 mg/kg/day) of oseltamivir over two generations. Traditional phenotypic and genotypic methods as well as deep sequencing analysis were used to characterize potential selection of mutations and population dynamics of oseltamivir-resistant variants. No oseltamivir-resistance NA or HA changes were detected in the recovered A/WSN/33 viruses. However, we observed a positive selection of the I222T NA substitution in the recovered A/Victoria/3/75 viruses, with a frequency increasing over time and with oseltamivir concentration from 4% in the initial pre-therapy inoculum up to 28% after two lung passages. Although the presence of mixed I222T viral populations in mouse lungs only led to a minimal increase in oseltamivir IC50 values (by a mean of 5.7 fold) compared to that of the baseline virus, the expressed recombinant A/Victoria/3/75 I222T NA protein displayed a 16-fold increase in oseltamivir IC50 level when compared to the recombinant WT. In conclusion, the combination of serial in vivo passages under NAI pressure and temporal deep sequencing analysis enabled, for the first time, the identification and selection of the oseltamivir-resistant I222T NA mutation in an influenza H3N2 virus. Additional in vivo selection experiments with other antivirals and drug combinations would provide important information on the evolution of antiviral resistance in influenza viruses.


http://aac.asm.org/content/early/2014/08/05/AAC.02956-14.abstract
 
Back
Top Bottom